Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 14/20 | 0.78 |
| ▸ | MKNK2 | Q9HBH9 | 14/20 | 0.78 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | BTK | Q06187 | 1/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
| ▸ | KMO | O15229 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10024284 | 0.86 | MKNK1 (0.62) | MKNK1MKNK2SLC2A1KMO | |
| SCHEMBL28258123 | 0.84 | MKNK1 (0.72) | MKNK1MKNK2SIRT3TDP1BTK | |
| SCHEMBL5305039 | 0.83 | MKNK1 (0.68) | MKNK1MKNK2KMO | |
| SCHEMBL3343643 | 0.83 | MKNK1 (0.54) | MKNK1MKNK2SIRT3TDP1BTK | |
| SCHEMBL15818270 | 0.82 | MKNK1 (0.69) | MKNK1MKNK2SIRT3TDP1BTK | |
| SCHEMBL17067114 | 0.82 | MKNK1 (0.67) | MKNK1MKNK2KMO | |
| SCHEMBL3346810 | 0.81 | MKNK1 (0.52) | MKNK1MKNK2SIRT3TDP1KCNH2 | |
| SCHEMBL3342702 | 0.81 | CHUK (0.68) | MKNK1MKNK2SIRT3TDP1BTK | |
| SCHEMBL7120106 | 0.80 | IKBKB (0.66) | MKNK1MKNK2 | |
| SCHEMBL4027305 | 0.80 | MMP2 (0.60) | MKNK1MKNK2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | claimed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | claimed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | claimed |
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | PIK3CA, AKT3, AKT1 | MKNK1 243/4885MKNK2 485/4885SIRT3 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.